A new market research report on the Global Non-Alcoholic Steatohepatitis market has introduced by KD Market Insights. The report is dedicated to in-depth industry analysis of the global Non-Alcoholic Steatohepatitis market. The Global Non-Alcoholic Steatohepatitis analysis is broken down on different segmentation levels including Market By Drug Type, By Sales Channel.
The global non-alcoholic steatohepatitis market generated $1,179 million in 2017, and is projected to reach $21,478 million by 2025, growing at a CAGR of 58.4% from 2021 to 2025. Nonalcoholic steatohepatitis is a form of liver disease that develops in patients who are not alcoholic. The major feature in NASH is fat deposition in the liver, along with inflammation and damage to the liver. Most patients with NASH are not aware that they are suffering from a liver problem. However, NASH can become severe and can lead to cirrhosis, in which the liver is permanently damaged.
Get Report Sample Copy @ https://www.kdmarketinsights.com/sample/4124
The nonalcoholic steatohepatitis market is expected to show double digit growth during the forecast period owing to increase in prevalence of NASH across the world, strong presence of ideal pipeline molecules, higher number of unmet needs, and growth in awareness of NASH therapeutics in the developing region. Furthermore, rise in prevalence of diabetes & obesity and growth in demand for ideal therapeutics are expected to influence the market growth in near future. On the other side, lack of diagnostic technologies for NASH limit the growth of the market.
The global non-alcoholic steatohepatitis (NASH) market is segmented based on drug type, sales channel, and region. Based on drug type, the market is divided as vitamin E & pioglitazone, ocaliva, elafibranor, and selonsertib & cenicriviroc. According to sales channel, the market is classified into hospital pharmacy, online provider and retail pharmacy. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
KEY BENEFITS
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
- A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Drug Type
- Vitamin E & Pioglitazone
- Obeticholic Acid (OCA)
- Elafibranor
- Selonsertib & Cenicriviroc
By Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
By Region
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
- Allergan plc. (Tobira Therapeutics)
- Cadila Healthcare Limited
- Conatus Pharmaceuticals Inc.
- Galmed Pharmaceuticals Ltd
- Gemphire Therapeutics Inc.
- Genfit SA
- Gilead Sciences, Inc.
- Intercept Pharmaceuticals, Inc.
- Novartis International AG
- Shire Plc.
Access Complete Research Report with TOC @ https://www.kdmarketinsights.com/product/non-alcoholic-steatohepatitis-market-amr
Table of Content
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets, 2021
3.2.2. Top player positioning
3.3. Top winning strategies
3.4. MARKET DYNAMICS
3.4.1. Drivers
3.4.1.1. Upsurge in NASH-affected population
3.4.1.2. Rise in prevalence of diabetes & obesity
3.4.1.3. Surge in healthcare expenditures worldwide
3.4.2. Restraints
3.4.2.1. Insufficient diagnostic technologies for NASH
3.4.2.2. Poor demand in the underdeveloped countries
3.4.3. Opportunities
3.4.3.1. Strong presence of pipeline drugs
3.4.3.2. Unmet needs for NASH therapeutics
3.4.3.3. Growth opportunities in the emerging markets
3.4.4. Impact analyses
3.5. Pipeline analyses
CHAPTER 4: NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Vitamin E & pioglitazone
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.3. Obeticholic acid
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.4. Elafibranor
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.5. Selonsertib & cenicriviroc
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
CHAPTER 5: NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY SALES CHANNEL
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospital pharmacy
5.2.1. Market size and forecast, by region
5.3. Online providers
5.3.1. Market size and forecast, by region
5.4. Retail pharmacy
5.4.1. Market size and forecast, by region
CHAPTER 6: NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by country
6.2.2.1. U.S. market size and forecast
6.2.2.2. Canada market size and forecast
6.2.2.3. Mexico market size and forecast
6.2.3. North America nonalcoholic steatohepatitis (NASH) market, by drug type
6.2.4. North America nonalcoholic steatohepatitis (NASH) market, by sales channel
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by country
6.3.2.1. Germany market size and forecast
6.3.2.2. France market size and forecast
6.3.2.3. UK market size and forecast
6.3.2.4. Italy market size and forecast
6.3.2.5. Spain market size and forecast
6.3.2.6. Rest of Europe market size and forecast
6.3.3. Europe nonalcoholic steatohepatitis (NASH) market, by drug type
6.3.4. Europe nonalcoholic steatohepatitis (NASH) market, by sales channel
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by country
6.4.2.1. Japan market size and forecast
6.4.2.2. China market size and forecast
6.4.2.3. Australia market size and forecast
6.4.2.4. India market size and forecast
6.4.2.5. South Korea market size and forecast
6.4.2.6. Rest of Asia-Pacific market size and forecast
6.4.3. Asia-Pacific nonalcoholic steatohepatitis (NASH) market, by drug type
6.4.4. Asia-Pacific nonalcoholic steatohepatitis (NASH) market, by sales channel
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by country
6.5.2.1. Brazil market size and forecast
6.5.2.2. Saudi Arabia market size and forecast
6.5.2.3. South Africa market size and forecast
6.5.2.4. Rest of LAMEA market size and forecast
6.5.3. LAMEA nonalcoholic steatohepatitis (NASH) market, by drug type
6.5.4. LAMEA nonalcoholic steatohepatitis (NASH) market, by sales channel
CHAPTER 7: COMPANY PROFILES
7.1. Allergan Plc (Tobira Therapeutics Inc.)
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. Cadila Healthcare Ltd.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Product portfolio
7.2.4. Business performance
7.3. Conatus Pharmaceuticals, Inc.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments
7.4. Galmed Pharmaceuticals Ltd.
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
Continue @...
Check for Discount @ https://www.kdmarketinsights.com/discount/4124
About Us:
KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market.
Contact Us:
KD Market Insights
150 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: sales@kdmarketinsights.com
Website: http://www.kdmarketinsights.com
Read More:
https://pr-wire.blogspot.com/
https://dailyprpost.blogspot.com/
The global non-alcoholic steatohepatitis market generated $1,179 million in 2017, and is projected to reach $21,478 million by 2025, growing at a CAGR of 58.4% from 2021 to 2025. Nonalcoholic steatohepatitis is a form of liver disease that develops in patients who are not alcoholic. The major feature in NASH is fat deposition in the liver, along with inflammation and damage to the liver. Most patients with NASH are not aware that they are suffering from a liver problem. However, NASH can become severe and can lead to cirrhosis, in which the liver is permanently damaged.
Get Report Sample Copy @ https://www.kdmarketinsights.com/sample/4124
The nonalcoholic steatohepatitis market is expected to show double digit growth during the forecast period owing to increase in prevalence of NASH across the world, strong presence of ideal pipeline molecules, higher number of unmet needs, and growth in awareness of NASH therapeutics in the developing region. Furthermore, rise in prevalence of diabetes & obesity and growth in demand for ideal therapeutics are expected to influence the market growth in near future. On the other side, lack of diagnostic technologies for NASH limit the growth of the market.
The global non-alcoholic steatohepatitis (NASH) market is segmented based on drug type, sales channel, and region. Based on drug type, the market is divided as vitamin E & pioglitazone, ocaliva, elafibranor, and selonsertib & cenicriviroc. According to sales channel, the market is classified into hospital pharmacy, online provider and retail pharmacy. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
KEY BENEFITS
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
- A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Drug Type
- Vitamin E & Pioglitazone
- Obeticholic Acid (OCA)
- Elafibranor
- Selonsertib & Cenicriviroc
By Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
By Region
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
- Allergan plc. (Tobira Therapeutics)
- Cadila Healthcare Limited
- Conatus Pharmaceuticals Inc.
- Galmed Pharmaceuticals Ltd
- Gemphire Therapeutics Inc.
- Genfit SA
- Gilead Sciences, Inc.
- Intercept Pharmaceuticals, Inc.
- Novartis International AG
- Shire Plc.
Access Complete Research Report with TOC @ https://www.kdmarketinsights.com/product/non-alcoholic-steatohepatitis-market-amr
Table of Content
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets, 2021
3.2.2. Top player positioning
3.3. Top winning strategies
3.4. MARKET DYNAMICS
3.4.1. Drivers
3.4.1.1. Upsurge in NASH-affected population
3.4.1.2. Rise in prevalence of diabetes & obesity
3.4.1.3. Surge in healthcare expenditures worldwide
3.4.2. Restraints
3.4.2.1. Insufficient diagnostic technologies for NASH
3.4.2.2. Poor demand in the underdeveloped countries
3.4.3. Opportunities
3.4.3.1. Strong presence of pipeline drugs
3.4.3.2. Unmet needs for NASH therapeutics
3.4.3.3. Growth opportunities in the emerging markets
3.4.4. Impact analyses
3.5. Pipeline analyses
CHAPTER 4: NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Vitamin E & pioglitazone
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.3. Obeticholic acid
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.4. Elafibranor
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.5. Selonsertib & cenicriviroc
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
CHAPTER 5: NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY SALES CHANNEL
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospital pharmacy
5.2.1. Market size and forecast, by region
5.3. Online providers
5.3.1. Market size and forecast, by region
5.4. Retail pharmacy
5.4.1. Market size and forecast, by region
CHAPTER 6: NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by country
6.2.2.1. U.S. market size and forecast
6.2.2.2. Canada market size and forecast
6.2.2.3. Mexico market size and forecast
6.2.3. North America nonalcoholic steatohepatitis (NASH) market, by drug type
6.2.4. North America nonalcoholic steatohepatitis (NASH) market, by sales channel
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by country
6.3.2.1. Germany market size and forecast
6.3.2.2. France market size and forecast
6.3.2.3. UK market size and forecast
6.3.2.4. Italy market size and forecast
6.3.2.5. Spain market size and forecast
6.3.2.6. Rest of Europe market size and forecast
6.3.3. Europe nonalcoholic steatohepatitis (NASH) market, by drug type
6.3.4. Europe nonalcoholic steatohepatitis (NASH) market, by sales channel
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by country
6.4.2.1. Japan market size and forecast
6.4.2.2. China market size and forecast
6.4.2.3. Australia market size and forecast
6.4.2.4. India market size and forecast
6.4.2.5. South Korea market size and forecast
6.4.2.6. Rest of Asia-Pacific market size and forecast
6.4.3. Asia-Pacific nonalcoholic steatohepatitis (NASH) market, by drug type
6.4.4. Asia-Pacific nonalcoholic steatohepatitis (NASH) market, by sales channel
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by country
6.5.2.1. Brazil market size and forecast
6.5.2.2. Saudi Arabia market size and forecast
6.5.2.3. South Africa market size and forecast
6.5.2.4. Rest of LAMEA market size and forecast
6.5.3. LAMEA nonalcoholic steatohepatitis (NASH) market, by drug type
6.5.4. LAMEA nonalcoholic steatohepatitis (NASH) market, by sales channel
CHAPTER 7: COMPANY PROFILES
7.1. Allergan Plc (Tobira Therapeutics Inc.)
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. Cadila Healthcare Ltd.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Product portfolio
7.2.4. Business performance
7.3. Conatus Pharmaceuticals, Inc.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments
7.4. Galmed Pharmaceuticals Ltd.
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
Continue @...
Check for Discount @ https://www.kdmarketinsights.com/discount/4124
About Us:
KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market.
Contact Us:
KD Market Insights
150 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: sales@kdmarketinsights.com
Website: http://www.kdmarketinsights.com
Read More:
https://pr-wire.blogspot.com/
https://dailyprpost.blogspot.com/
No comments:
Post a Comment